4D Molecular Therapeutics Income Statement (2019-2026) | FDMT

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
14.58M1.37M0.09M1.22M0.16M0.50M1.25M0.30M0.24M20.20M-0.02M0.03M0.01M0.00M0.00M0.01M0.01M0.09M85.09M3.05M
Operating items
Research & Development (Quarter)
15.22M15.84M17.53M19.38M20.42M18.94M21.50M22.41M23.58M25.07M26.03M27.87M31.86M38.48M43.09M40.70M47.95M49.44M57.61M64.98M
Selling, General & Administrative (Quarter)
6.95M8.19M7.33M8.23M8.17M8.05M8.47M7.99M8.79M9.11M10.61M10.29M10.60M12.65M13.03M12.94M11.52M11.84M12.77M11.69M
Operating Expenses (Quarter)
22.18M24.03M24.86M27.61M28.59M27.00M29.97M30.40M32.38M34.18M36.63M38.16M42.46M51.13M56.12M53.63M59.47M61.27M70.38M76.67M
Operating Income (Quarter)
-7.60M-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M-73.62M
EBIT (Quarter)
-7.60M-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M-73.62M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.43M-0.31M-1.00M-0.41M0.80M1.34M0.93M0.61M3.88M4.38M-0.12M-0.18M7.29M6.47M5.58M0.01M4.33M4.70M4.86M
Other Non Operating Income (Quarter)
-0.01M-0.01M-0.05M0.01M0.00M-0.02M0.01M-0.16M-0.01M-0.01M-0.04M-0.00M-0.02M0.07M-0.06M-0.02M-0.02M-0.00M
Non Operating Income (Quarter)
0.01M0.42M-0.32M0.05M0.34M0.80M1.34M1.42M2.52M3.72M4.37M5.74M7.50M7.29M6.45M5.65M4.80M4.31M4.68M4.86M
Net income details
EBT (Quarter)
-10.79M-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M
Profit After Tax (Quarter)
-7.59M-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M-68.76M
Income from Continuing Operations (Quarter)
-10.79M-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M
Consolidated Net Income (Quarter)
-10.79M-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M
Income towards Parent Company (Quarter)
-10.79M-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M
Net Income towards Common Stockholders (Quarter)
-7.59M-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M-68.76M
Additional items
EPS (Basic) (Quarter)
-0.28-0.82-0.90-0.82-0.87-0.79-0.85-0.88-0.77-0.24-0.83-0.66-0.63-0.79-0.92-0.86-0.98-1.010.33-1.01
EPS (Diluted) (Quarter)
-0.28-0.82-0.90-0.82-0.87-0.79-0.85-0.88-0.77-0.24-0.83-0.66-0.63-0.79-0.92-0.86-0.98-1.010.33-1.01
Shares Outstanding (Quarter)
26.74M27.02M27.73M32.23M32.32M32.39M32.35M32.72M38.34M42.26M39.13M49.27M55.28M55.55M53.94M55.74M55.93M56.13M57.93M68.06M
Shares Outstanding (Diluted) (Quarter)
26.74M27.02M27.73M32.23M32.32M32.39M32.35M32.72M38.34M42.26M39.13M49.27M55.28M55.55M53.94M55.74M55.93M56.13M57.93M68.06M
EBITDA (Quarter)
-7.60M-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M-73.62M
Interest Expenses (Quarter)
3.21M25.31M1.20M5.74M5.39M21.62M2.90M20.11M19.75M18.99M0.80M0.80M2.81M34.11M0.90M1.40M30.44M29.02M1.40M26.16M